Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 227 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Pulmonary Arterial Hypertension - Overview 9
Pulmonary Arterial Hypertension - Therapeutics Development 10
Pipeline Overview 10
Pipeline by Companies 11
Pipeline by Universities/Institutes 15
Products under Development by Companies 16
Products under Development by Universities/Institutes 20
Pulmonary Arterial Hypertension - Therapeutics Assessment 21
Assessment by Target 21
Assessment by Mechanism of Action 24
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 31
Actelion Ltd 31
APT Therapeutics Inc 31
Arena Pharmaceuticals Inc 32
Ascendis Pharma A/S 32
Asklepion Pharmaceuticals LLC 33
AVEO Pharmaceuticals Inc 33
Bial - Portela & Ca SA 34
Camurus AB 34
Celsion Corp 35
Celtaxsys Inc 35
Chiesi Farmaceutici SpA 36
Eli Lilly and Company 36
F. Hoffmann-La Roche Ltd 37
Galectin Therapeutics Inc 37
HitGen LTD 38
Insmed Inc 38
INSYS Therapeutics Inc 39
INVENT Pharmaceuticals Inc 39
Johnson & Johnson 40
Kowa Company Ltd 40
Liquidia Technologies Inc 41
MannKind Corp 41
Mast Therapeutics Inc 42
Mezzion Pharma Co Ltd 42
miRagen Therapeutics Inc 43
Morphogen-IX Ltd 43
Nippon Kayaku Co Ltd 44
Nippon Shinyaku Co Ltd 44
Northern Therapeutics Inc 45
Novartis AG 45
Peloton Therapeutics Inc 46
PhaseBio Pharmaceuticals Inc 46
Pluristem Therapeutics Inc 47
Polyphor Ltd 47
Proteo Inc 48
Pulmokine Inc 48
Reata Pharmaceuticals Inc 49
Respira Therapeutics Inc 49
Reviva Pharmaceuticals Inc 50
Selten Pharma Inc 50
Serodus ASA 51
Silence Therapeutics Plc 51
SteadyMed Therapeutics Inc 52
Suda Ltd 52
Toray Industries Inc 53
United Therapeutics Corp 53
Vivus Inc 54
Pulmonary Arterial Hypertension - Drug Profiles 55
(macitentan + tadalafil) - Drug Profile 55
acebilustat - Drug Profile 56
Antibody to Inhibit TRAIL for Pulmonary Arterial Hypertension - Drug Profile 60
Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 61
APT-602 - Drug Profile 62
ascomycin - Drug Profile 63
AV-353 - Drug Profile 64
bardoxolone methyl - Drug Profile 65
beraprost sodium SR - Drug Profile 71
BIA-51058 - Drug Profile 72
BMP-10 - Drug Profile 73
BMP-9 - Drug Profile 74
Cell Therapy to Activate eNOS for Pulmonary Arterial Hypertension - Drug Profile 75
CTX-3397 - Drug Profile 76
Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 77
esuberaprost sodium MR + treprostinil - Drug Profile 78
GMA-301 - Drug Profile 79
GMCT-01 - Drug Profile 80
GRMD-02 - Drug Profile 84
INS-1009 - Drug Profile 97
INV-240 - Drug Profile 99
JNJ-26993135 - Drug Profile 100
KAR-5585 - Drug Profile 101
L-Citrulline - Drug Profile 102
macitentan - Drug Profile 104
MD-0701 - Drug Profile 110
MFC-1040 - Drug Profile 112
MFC-2040 - Drug Profile 113
NK-104 NP - Drug Profile 114
Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile 115
Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 116
PB-1046 - Drug Profile 117
PB-1120 - Drug Profile 120
PF-543 - Drug Profile 121
PK-10453 - Drug Profile 122
PK-10571 - Drug Profile 123
PLX-PAD - Drug Profile 124
POL-6014 - Drug Profile 135
PT-2977 - Drug Profile 137
QCC-374 - Drug Profile 138
R-190 - Drug Profile 139
ralinepag - Drug Profile 141
RP-5063 - Drug Profile 143
RT-234 - Drug Profile 145
selexipag - Drug Profile 146
SER-100 - Drug Profile 151
sildenafil citrate - Drug Profile 154
sirolimus - Drug Profile 155
sirolimus albumin-bound - Drug Profile 156
Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158
Small Molecules for Pulmonary Arterial Hypertension - Drug Profile 159
Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 160
Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 161
Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 162
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 163
sodium nitrite - Drug Profile 164
SPI-054 - Drug Profile 168
SPI-183 - Drug Profile 169
SUD-004 - Drug Profile 170
Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 171
tacrolimus - Drug Profile 172
tadalafil - Drug Profile 173
tiprelestat - Drug Profile 175
tocilizumab - Drug Profile 179
TPN-729 - Drug Profile 189
TR-422 - Drug Profile 190
treprostinil diolamine - Drug Profile 191
treprostinil diolamine - Drug Profile 193
treprostinil diolamine - Drug Profile 195
treprostinil diolamine - Drug Profile 196
treprostinil diolamine SR - Drug Profile 197
ubenimex - Drug Profile 198
udenafil - Drug Profile 200
VPD-380 - Drug Profile 204
Pulmonary Arterial Hypertension - Dormant Projects 205
Pulmonary Arterial Hypertension - Discontinued Products 207
Pulmonary Arterial Hypertension - Product Development Milestones 208
Featured News & Press Releases 208
Appendix 220
Methodology 220
Coverage 220
Secondary Research 220
Primary Research 220
Expert Panel Validation 220
Contact Us 220
Disclaimer 221

List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017
Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2017
Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by INSYS Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Kowa Company Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Proteo Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Selten Pharma Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H1 2017
Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H1 2017
Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H1 2017
Pulmonary Arterial Hypertension - Dormant Projects, H1 2017
Pulmonary Arterial Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017
Pulmonary Arterial Hypertension - Discontinued Products, H1 2017